Cargando…
Addition of Tolcapone in Intrajejunal Levodopa Infusion Therapy Requires a Pronounced Dose Reduction
Autores principales: | Schröter, Nils, Ahrendt, Sabine, Hager, Anna, Rijntjes, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534000/ https://www.ncbi.nlm.nih.gov/pubmed/33033740 http://dx.doi.org/10.1002/mdc3.13029 |
Ejemplares similares
-
Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020) -
Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021) -
Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023) -
Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
por: van Poppelen, Daniël, et al.
Publicado: (2021) -
Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
por: Kataoka, Hiroshi, et al.
Publicado: (2017)